Malaria research

“Be the change you want to see in the world.”

— Mahatma Gandhi

Malaria remains a leading cause of illness and death in sub-Saharan Africa, disproportionately affecting children under five years of age. Despite existing treatments and preventive measures, the disease continues to pose significant health challenges.

Innovative Approach: PC240m

PC240m is a resonance developed to support people suffering from malaria and has been in use since 2002. Early observations in Malawi indicated that patients who were using PC240m for their welbeing also remained free of malaria attacks for six months or longer. This anecdotal finding is very promising and asked for follow up research.

Malaria continues to claim lives in sub-Saharan Africa, particularly among young children. ARHF’s fieldwork demonstrates that PC240m — a natural, resonance-based product — can be benefitial to support communities. Initial data from regions where the resonance has been distributed shows a remarkable outcomes.

Malaria continues to claim lives in sub-Saharan Africa, particularly among young children. ARHF’s fieldwork demonstrates that PC240m —a natural, resonance-based product — can be benefitial to support communities. Initial data from regions where the resonance has been distributed shows a remarkable outcomes.

The implementation of PC240m in various regions has yielded promising results.

What we see in practice and what it means for the community

DR Congo (2009)

At a school in South Kivu, 600 children were regularly administered PC Malaria. Within a few months, the school management reported no more malaria cases. In a small Congolese town, PC Malaria was administered in the community, prompting the local Red Cross hospital to report a 95% reduction in malaria cases.

Malawi (2012)

A daycare center caring for 300 children lost five children to malaria each year. The year they started administering PC240m to all children, they reported that non  of their children died from malaria.

Kenya (2014)

After the introduction of PC240m in a 20,000 people community a six month period followed without people dying from malaria. A local carpenter, who previously made several coffins a week, noticed a lack of demand and switched to a new profession. [1]

Africa Malaria Prevention Project (AMPP)

Building on these results, ARHF launched the Africa Malaria Prevention Project (AMPP) in 2013, with the goal of providing  an accessible, cheap product to support  people suffering from malaria. After offering AMPP to 27,000 people in Malawi, schools reported reduced absenteeism, while local hospitals saw a reduction in hospitalizations and deaths from malaria. [1]

Epidemiological Study in Bukavu, DR Congo (2018-2023)

A non-randomized outcome study was conducted in Kadutu Commune, comprising 13 Health Areas (HAs). The results are as follows:

Malaria-related hospitalizations (see graph)

  • HA 1-5 (AMPP 2019-2023); malaria cases decreased by 36% in 2022 and 30% in 2023 compared to 2018.
  • HA 6-10 (non-AMPP 2019-2022); malaria cases increased by 17% in 2022 compared to 2018. After the implementation of the AMPP in 2023, malaria cases decreased by 37%.
  • HA 11-13 (non-AMPP 2019-2023); Malaria cases increased by 33% in 2022 and decreased by 10% in 2023.

Malaria cases per 1000 (all ages)

Malaria-related deaths (see graph)

  • HA 1-5 (AMPP from 2019-2023): deaths decreased by 72% in 2022 and 79% in 2023 compared to 2018.
  • HA 6-10 (non-AMPP from 2019-2022): deaths increased by 12% in 2022 compared to 2018. After the implementation of the AMPP, malaria deaths decreased by 30%.
  • HA 11-13 (non-AMPP from 2019-2023). In 2022, the number of malaria deaths remained unchanged, then decreased by 17% in 2023 compared to 2018.

Malaria deaths per 1000 (all ages)

Conclusion:

The findings from the epidemiological observations in Bukavu are consistent with a possible association between the use of PC240m and changes in malaria-related health outcomes, including reported malaria cases, hospitalisations and deaths.

In 2022, when approximately 35% of the population in Health Areas (HAs) 1–5 was included in the AMPP programme, a 36% reduction in reported malaria cases and a 72% reduction in malaria-related deaths were observed compared with the relevant baseline period.

These findings are encouraging and warrant further investigation. However, as this was an epidemiological outcomes study conducted under real-world conditions and not a randomized controlled trial, the observed changes cannot by themselves establish that PC240m caused the reductions. Other factors, including changes in malaria transmission, healthcare access, diagnosis, treatment and reporting, may also have contributed to the observed outcomes. [2]

ARHF – A story of Love and Hope

References

  1. Van der Zee HE (2016). Africa Malaria Prevention Project. Homoeopathic Links 2016;29(2):137–146.
  2. Van der Zee HE, Alimasi DB, Balikwisha JN, Walach H (2025). Novel Immune Supportive Prevention of Malaria, Data Collection Research in the city of Bukavu (DR Congo). International Journal of Malaria and Tropical Diseases (IJMTD) Vol. 6(1):113-121